Program:

• ELN 2020 treatment milestones
• First-line therapy
• ELN definitions of failure
• ELN 2020 recommendations on treatment beyond 2nd line
• Recommendations for switch: CP-CML
• Biological features of progression
• Treatment-free remission
• TKI and pregnancy
• Strategic positioning of the new TKI: Asciminib
• Overview of ELN Recommendations through the years

Professor Andreas Hochhaus has personally answered the questions asked during the webinar. His answers can be found to the pdf